Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.

Abstract: A method for sterilizing biological materials is disclosed. A dehydrated biological material is put into a closed container. The closed container is then decompressed under a vacuum. Subsequently, 0.01 g/m3 to 1000 g/m3 of a sterilizing gas, i.e., pure ozone, is introduced into the container for a period of time until the biological material is sterilized.

Abstract: This invention discloses a method for stabilizing bioactivity of a growth factor, including mixing collagen with a growth factor and freeze drying the mixture to remove water. After this treatment, the bioactivity of the growth factor at room temperature remains stable for at least 7 days.

Abstract: A biological scaffold in the present invention comprises a main body, a biological material layer, and an optional tissue adhesive layer. The main body at least has a non-constituted collagen matrix. The biological material layer is coated at least on a surface of the main body, and the tissue adhesive layer is disposed at least on another surface of the main body. When the biological scaffold is adhered to a tissue through the tissue adhesive layer, a plurality of cells move from the tissue to either the adhesive layer or the biological material layer for tissue repairing or regeneration.

Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.

Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a thrombolytic drug and the matrix component includes a hyaluronan or derivative thereof, the matrix component having a viscosity greater than 10 mPa·s.

Abstract: A method of treating a keloid in a subject, comprising: applying a pharmaceutical composition to a keloid or an area at risk of forming a keloid in a subject, wherein the composition includes an effective amount of a hyaluronan and an effective amount of a collagen, the weight ratio per unit volume of the hyaluronan to the collagen being greater than 1.

Abstract: A method for sterilizing biological materials is disclosed. A dehydrated biological material is put into a closed container. The closed container is then decompressed under a vacuum. Subsequently, 0.01 g/m3 to 1000 g/m3 of a sterilizing gas, i.e., pure ozone, is introduced into the container for a period of time until the biological material is sterilized.

Abstract: A method for sterilizing biological materials is disclosed. After dehydrating the biological material, the dehydrated biological material is put into a closed container, and 0.01 g/m3 to 1000 g/m3 or an enough dose of ozone gas is introduced into the container for a period of time until the biological material is completely sterilized. Afterward, the ozone gas is removed from the closed container to finish sterilization of the biological material.

Abstract: A cell tissue gel, comprising one or more matrix molecules cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent, wherein the quenching agent contains a moiety that is capable of reacting with the reactive group of the cross-linking agent and the one or more matrix molecules contain one or more functional groups that are capable of cross-linking with the reactive group, the amount of the reactive group of the cross-linking agent being equal to or less than a total amount including the amount of the one or more functional groups and the amount of the moiety.

Abstract: Described herein is a cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1.

Abstract: Described herein is a cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1.

Abstract: An ultrasonic oscillation machine for manufacturing porous collagen matrices has a hollow body, a vessel, a conveyor, multiple frames, multiple oscillation devices and an ultrasonic mechanism. The vessel is mounted in the body. The frames are connected to the conveyor. The conveyor moves the frames to leave from or to be put into the vessel. Each frame has multiple containers to carry subjects. The oscillation devices are connected respectively to the frames. The ultrasonic mechanism is mounted in the vessel. During the manufacturing process, the oscillation devices and the ultrasonic mechanism operate to provide affection. Then the connective tissues in the containers gradually become porous collagen matrices.

Abstract: Described herein is a cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1.

Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.

Abstract: A cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1 and uses thereof for stem cell delivery.

Abstract: A method for regulating proliferation of cells, has steps of providing a first culture system with a surface that is coated with a biological material; inoculating and culturing cells on the surface of the first culture system in an appropriate medium, such that the proliferation of the cells is preserved; collecting the cells; providing a second culture system with a surface; and inoculating and culturing the cells on the surface of the second culture system in a culture medium containing the biological material, such that the proliferation of the cells is promoted. A method for regulating proliferation of cells is also provided, the method being the same as the previous method except that the step of inoculating and culturing in a first culture system is performed before the step of inoculating and culturing in a second culture system.

Abstract: An ultrasonic oscillation machine for manufacturing porous collagen matrices has a hollow body, a vessel, a conveyor, multiple frames, multiple oscillation devices and an ultrasonic mechanism. The vessel is mounted in the body. The frames are connected to the conveyor. The conveyor moves the frames to leave from or to be put into the vessel. Each frame has multiple containers to carry subjects. The oscillation devices are connected respectively to the frames. The ultrasonic mechanism is mounted in the vessel. During the manufacturing process, the oscillation devices and the ultrasonic mechanism operate to provide affection. Then the connective tissues in the containers gradually become porous collagen matrices.

Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.

Abstract: Use of hyaluronan, either alone or in combination with collagen, for promoting angiogenesis.